CDT Equity has announced a SAFE investment in Pep'd, aiming to expand its footprint in the rapidly growing U.S. peptide market. This strategic move is expected to enhance CDT's presence in the American pharmaceutical sector.

CDT Equity has advanced AstraZeneca PLC (AZN)’s compound AZD5904 into the Patent Cooperation Treaty (PCT) patent protection stage.

Tianci International and CDT Equity have both announced plans for a 1-for-10 reverse stock split. This corporate action will consolidate existing shares into fewer, more valuable shares.

CDT Equity has announced a reverse stock split.

CDT Equity has announced a debt restructuring plan and secured a new loan facility of up to $1.46 million.